Otsuka and Lundbeck’s CNS drug Rexulti has for the second time this year claimed the top spot as the leading TV drug ad spender. That’s according to the latest data out by real-time ad trackers ...
Otsuka and its partner Lundbeck snagged an FDA approval for Rexulti (brexpiprazole) to treat schizophrenia and as an add-on therapy for major depression, leaving the two companies prepping for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results